- Home
- INKT vs ACXP Comparison
INKT vs ACXP Comparison
Compare INKT & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INKT | ACXP |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 6.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INKT | ACXP |
|---|---|---|
| Price | $12.02 | $3.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $35.00 | ★ $143.67 |
| AVG Volume (30 Days) | 21.3K | ★ 78.0K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.56 | $3.17 |
| 52 Week High | $76.00 | $25.00 |
Technical Indicators
Market Signals| Indicator | INKT | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 45.91 | 39.72 |
| Support Level | $11.55 | $3.98 |
| Resistance Level | $12.68 | $4.36 |
| Average True Range (ATR) | 0.87 | 0.36 |
| MACD | 0.14 | 0.04 |
| Stochastic Oscillator | 44.52 | 21.60 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.